Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank.
- 1Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
- 2Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
- 3Department of Cardiology, Cardiometabolic Center, State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
Background
Despite substantial reductions in cardiovascular events with intensive LDL-C lowering, significant residual risk persists. Remnant cholesterol (RC) and C-reactive protein (CRP) reflect lipid dysregulation and inflammation, respectively, and may synergistically promote atherosclerosis. However, large-scale cohort evidence on their combined impact, particularly the quantitative interaction between the two and the modifying role of cholesterol-lowering therapy, remains limited.Methods
This study included 376,817 participants with a median follow-up of 13.4 years. Cox proportional hazards regression models were used to evaluate the individual and joint associations of RC and CRP with major adverse cardiovascular events (MACE) risk. Stratified analyses by cholesterol-lowering therapy were further conducted to explore its modifying effect on the combined risk.Results
Both RC (≥0.8 mmol/L) and CRP (≥2 mg/L) were independently associated with MACE risk, with adjusted hazard ratios (HR) of 1.074 [95% confidence interval (CI): 1.024-1.126] and 1.168 (95% CI: 1.129-1.207), respectively. Concurrent elevation of both biomarkers conferred the highest risk (HR = 1.239, 95% CI: 1.167-1.316), and a significant positive multiplicative interaction was observed between RC and CRP. Stratified analyses suggested effect modification by cholesterol-lowering medication: the association between isolated RC elevation and MACE was attenuated in medication users, whereas risks remained significant for isolated CRP elevation and combined elevation of both markers.Conclusion
Concurrent elevation of RC and CRP yields the highest MACE risk with a positive additive interaction. Cholesterol-lowering therapy reduces RC-related risk but not inflammation-driven risk in isolated CRP elevation. These findings support combined assessment of both biomarkers for personalized cardiovascular risk stratification.
Related
- Association of the C-reactive protein–triglyceride–glucose index with adverse cardiovascular outcomes in patients with acute coronary syndrome and type 2 diabetes: findings from an observational cohort study in China
- Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives.
- Colchicine use and cardiovascular event risk in Chinese adults starting urate-lowering therapy: a cohort study
- Residual Risk From Remnant Cholesterol and Inflammation Despite Lipid‐Lowering Therapy and Association With Incident Peripheral Artery Disease in Type 2 Diabetes
- Comparative effectiveness of lipid-lowering therapies for primary cardiovascular prevention: a network meta-analysis of randomised controlled trials
BibTeX
@article{chen2026remnant,
title = {{Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank.}},
author = {Jing Chen and Xuan Song and Jian-Jun Li and Li-Chan Tao},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1920077},
url = {https://europepmc.org/article/MED/42898209},
note = {CC BY},
}
RIS
TY - JOUR
TI - Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank.
AU - Jing Chen
AU - Xuan Song
AU - Jian-Jun Li
AU - Li-Chan Tao
PY - 2026
DA - 2026/10/05
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1920077
UR - https://europepmc.org/article/MED/42898209
AB - Background Despite substantial reductions in cardiovascular events with intensive LDL-C lowering, significant residual risk persists. Remnant cholesterol (RC) and C-reactive protein (CRP) reflect lipid dysregulation and inflammation, respectively, and may synergistically promote atherosclerosis. However, large-scale cohort evidence on their combined impact, particularly the quantitative interaction between the two and the modifying role of cholesterol-lowering therapy, remains limited.Methods This study included 376,817 participants with a median follow-up of 13.4 years. Cox proportional hazards regression models were used to evaluate the individual and joint associations of RC and CRP with major adverse cardiovascular events (MACE) risk. Stratified analyses by cholesterol-lowering therapy were further conducted to explore its modifying effect on the combined risk.Results Both RC (≥0.8 mmol/L) and CRP (≥2 mg/L) were independently associated with MACE risk, with adjusted hazard ratios (HR) of 1.074 [95% confidence interval (CI): 1.024-1.126] and 1.168 (95% CI: 1.129-1.207), respectively. Concurrent elevation of both biomarkers conferred the highest risk (HR = 1.239, 95% CI: 1.167-1.316), and a significant positive multiplicative interaction was observed between RC and CRP. Stratified analyses suggested effect modification by cholesterol-lowering medication: the association between isolated RC elevation and MACE was attenuated in medication users, whereas risks remained significant for isolated CRP elevation and combined elevation of both markers.Conclusion Concurrent elevation of RC and CRP yields the highest MACE risk with a positive additive interaction. Cholesterol-lowering therapy reduces RC-related risk but not inflammation-driven risk in isolated CRP elevation. These findings support combined assessment of both biomarkers for personalized cardiovascular risk stratification.
SN - 2296-861X
ER -